Wiki2Web Studio

Create complete, beautiful interactive educational materials in less than 5 minutes.

Print flashcards, homework worksheets, exams/quizzes, study guides, & more.

Export your learner materials as an interactive game, a webpage, or FAQ style cheatsheet.

Unsaved Work Found!

It looks like you have unsaved work from a previous session. Would you like to restore it?

GSK plc: History and Corporate Development

At a Glance

Title: GSK plc: History and Corporate Development

Total Categories: 5

Category Stats

  • Origins and Early Development: 7 flashcards, 6 questions
  • Mergers and Corporate Formation: 4 flashcards, 6 questions
  • Business Portfolio and Strategic Moves: 14 flashcards, 19 questions
  • Legal, Ethical, and Regulatory Issues: 19 flashcards, 14 questions
  • Innovation, Leadership, and Global Presence: 14 flashcards, 15 questions

Total Stats

  • Total Flashcards: 59
  • True/False Questions: 30
  • Multiple Choice Questions: 30
  • Total Questions: 60

Instructions

Click the button to expand the instructions for how to use the Wiki2Web Teacher studio in order to print, edit, and export data about GSK plc: History and Corporate Development

Welcome to Your Curriculum Command Center

This guide will turn you into a Wiki2web Studio power user. Let's unlock the features designed to give you back your weekends.

The Core Concept: What is a "Kit"?

Think of a Kit as your all-in-one digital lesson plan. It's a single, portable file that contains every piece of content for a topic: your subject categories, a central image, all your flashcards, and all your questions. The true power of the Studio is speed—once a kit is made (or you import one), you are just minutes away from printing an entire set of coursework.

Getting Started is Simple:

  • Create New Kit: Start with a clean slate. Perfect for a brand-new lesson idea.
  • Import & Edit Existing Kit: Load a .json kit file from your computer to continue your work or to modify a kit created by a colleague.
  • Restore Session: The Studio automatically saves your progress in your browser. If you get interrupted, you can restore your unsaved work with one click.

Step 1: Laying the Foundation (The Authoring Tools)

This is where you build the core knowledge of your Kit. Use the left-side navigation panel to switch between these powerful authoring modules.

⚙️ Kit Manager: Your Kit's Identity

This is the high-level control panel for your project.

  • Kit Name: Give your Kit a clear title. This will appear on all your printed materials.
  • Master Image: Upload a custom cover image for your Kit. This is essential for giving your content a professional visual identity, and it's used as the main graphic when you export your Kit as an interactive game.
  • Topics: Create the structure for your lesson. Add topics like "Chapter 1," "Vocabulary," or "Key Formulas." All flashcards and questions will be organized under these topics.

🃏 Flashcard Author: Building the Knowledge Blocks

Flashcards are the fundamental concepts of your Kit. Create them here to define terms, list facts, or pose simple questions.

  • Click "➕ Add New Flashcard" to open the editor.
  • Fill in the term/question and the definition/answer.
  • Assign the flashcard to one of your pre-defined topics.
  • To edit or remove a flashcard, simply use the ✏️ (Edit) or ❌ (Delete) icons next to any entry in the list.

✍️ Question Author: Assessing Understanding

Create a bank of questions to test knowledge. These questions are the engine for your worksheets and exams.

  • Click "➕ Add New Question".
  • Choose a Type: True/False for quick checks or Multiple Choice for more complex assessments.
  • To edit an existing question, click the ✏️ icon. You can change the question text, options, correct answer, and explanation at any time.
  • The Explanation field is a powerful tool: the text you enter here will automatically appear on the teacher's answer key and on the Smart Study Guide, providing instant feedback.

🔗 Intelligent Mapper: The Smart Connection

This is the secret sauce of the Studio. The Mapper transforms your content from a simple list into an interconnected web of knowledge, automating the creation of amazing study guides.

  • Step 1: Select a question from the list on the left.
  • Step 2: In the right panel, click on every flashcard that contains a concept required to answer that question. They will turn green, indicating a successful link.
  • The Payoff: When you generate a Smart Study Guide, these linked flashcards will automatically appear under each question as "Related Concepts."

Step 2: The Magic (The Generator Suite)

You've built your content. Now, with a few clicks, turn it into a full suite of professional, ready-to-use materials. What used to take hours of formatting and copying-and-pasting can now be done in seconds.

🎓 Smart Study Guide Maker

Instantly create the ultimate review document. It combines your questions, the correct answers, your detailed explanations, and all the "Related Concepts" you linked in the Mapper into one cohesive, printable guide.

📝 Worksheet & 📄 Exam Builder

Generate unique assessments every time. The questions and multiple-choice options are randomized automatically. Simply select your topics, choose how many questions you need, and generate:

  • A Student Version, clean and ready for quizzing.
  • A Teacher Version, complete with a detailed answer key and the explanations you wrote.

🖨️ Flashcard Printer

Forget wrestling with table layouts in a word processor. Select a topic, choose a cards-per-page layout, and instantly generate perfectly formatted, print-ready flashcard sheets.

Step 3: Saving and Collaborating

  • 💾 Export & Save Kit: This is your primary save function. It downloads the entire Kit (content, images, and all) to your computer as a single .json file. Use this to create permanent backups and share your work with others.
  • ➕ Import & Merge Kit: Combine your work. You can merge a colleague's Kit into your own or combine two of your lessons into a larger review Kit.

You're now ready to reclaim your time.

You're not just a teacher; you're a curriculum designer, and this is your Studio.

This page is an interactive visualization based on the Wikipedia article "GSK plc" (opens in new tab) and its cited references.

Text content is available under the Creative Commons Attribution-ShareAlike 4.0 License (opens in new tab). Additional terms may apply.

Disclaimer: This website is for informational purposes only and does not constitute any kind of advice. The information is not a substitute for consulting official sources or records or seeking advice from qualified professionals.


Owned and operated by Artificial General Intelligence LLC, a Michigan Registered LLC
Prompt engineering done with Gracekits.com
All rights reserved
Sitemaps | Contact

Export Options





Study Guide: GSK plc: History and Corporate Development

Study Guide: GSK plc: History and Corporate Development

Origins and Early Development

Glaxo originated in London in the early 1900s, focusing initially on pharmaceutical research.

Answer: False

Glaxo originated in New Zealand in 1873 as Joseph Nathan and Co., later becoming Glaxo Laboratories in London, with its initial significant product being a dried-milk baby food.

Related Concepts:

  • When did Glaxo Laboratories become a distinct subsidiary, and when did it obtain a listing on the London Stock Exchange?: Glaxo Laboratories was incorporated as a distinct subsidiary in London in 1935. The company obtained a listing on the London Stock Exchange in 1947 after its shareholders reorganized the group's structure.
  • How did the company Glaxo originate, and what was its initial product that gained significant recognition?: Glaxo originated as Joseph Nathan and Co., founded in New Zealand in 1873. It began producing a dried-milk baby food called "Glaxo" in 1904, marketed with the slogan "Glaxo builds bonnie babies."
  • What is GSK plc, and what is its primary business sector?: GSK plc, formerly known as GlaxoSmithKline plc, is a British multinational pharmaceutical and biotechnology company. It focuses on developing and manufacturing medicines and vaccines.

Glaxo Laboratories obtained a listing on the London Stock Exchange in 1935.

Answer: False

Glaxo Laboratories was incorporated as a distinct subsidiary in London in 1935, but it obtained its listing on the London Stock Exchange in 1947.

Related Concepts:

  • When did Glaxo Laboratories become a distinct subsidiary, and when did it obtain a listing on the London Stock Exchange?: Glaxo Laboratories was incorporated as a distinct subsidiary in London in 1935. The company obtained a listing on the London Stock Exchange in 1947 after its shareholders reorganized the group's structure.
  • Which company did Glaxo acquire in 1958, and who was a notable scientist hired shortly after this acquisition?: Glaxo acquired Allen & Hanburys in 1958. Scottish pharmacologist David Jack was hired by Allen & Hanburys a few years later and eventually led Glaxo's research and development.
  • What significant merger occurred in 1995 that led to the formation of Glaxo Wellcome plc?: In 1995, Glaxo and Wellcome merged to form Glaxo Wellcome plc, a move that was considered the largest corporate merger in the UK at that time.

Beecham Group was founded by Thomas Beecham in 1848, initially selling patent medicines.

Answer: True

Thomas Beecham founded the Beecham Group in 1848, commencing operations with the sale of patent medicines, notably Beecham's Pills.

Related Concepts:

  • Who founded Beecham Group, and what was its initial product?: Beecham Group was founded by Thomas Beecham in 1848, who launched his Beecham's Pills laxative in England.
  • What areas was Beecham extensively involved in by the 1960s?: By the 1960s, Beecham was extensively involved in pharmaceuticals, consumer products like Macleans toothpaste and Lucozade, and research into synthetic penicillin.

By the 1960s, Beecham was primarily focused on consumer products like toothpaste and beverages.

Answer: False

While Beecham was involved in consumer products, by the 1960s, it was also extensively involved in pharmaceuticals and research into synthetic penicillin, not solely focused on consumer goods.

Related Concepts:

  • What areas was Beecham extensively involved in by the 1960s?: By the 1960s, Beecham was extensively involved in pharmaceuticals, consumer products like Macleans toothpaste and Lucozade, and research into synthetic penicillin.
  • Who founded Beecham Group, and what was its initial product?: Beecham Group was founded by Thomas Beecham in 1848, who launched his Beecham's Pills laxative in England.

What was the initial product that gained significant recognition for the company that originated as Joseph Nathan and Co. (later Glaxo)?

Answer: A dried-milk baby food called "Glaxo"

The company that originated as Joseph Nathan and Co. (later Glaxo) gained significant recognition for its initial product: a dried-milk baby food marketed as "Glaxo."

Related Concepts:

  • How did the company Glaxo originate, and what was its initial product that gained significant recognition?: Glaxo originated as Joseph Nathan and Co., founded in New Zealand in 1873. It began producing a dried-milk baby food called "Glaxo" in 1904, marketed with the slogan "Glaxo builds bonnie babies."
  • When did Glaxo Laboratories become a distinct subsidiary, and when did it obtain a listing on the London Stock Exchange?: Glaxo Laboratories was incorporated as a distinct subsidiary in London in 1935. The company obtained a listing on the London Stock Exchange in 1947 after its shareholders reorganized the group's structure.
  • What were some of the key pharmaceutical products developed by Glaxo Wellcome by 1999, and in which therapeutic areas was it a leading manufacturer?: By 1999, Glaxo Wellcome's products included Imigran (migraine), salbutamol (Ventolin) for asthma, Zovirax for cold sores, and Retrovir and Epivir for AIDS. The company was the world's largest manufacturer of drugs for asthma and HIV/AIDS.

What was the initial product launched by Thomas Beecham in 1848?

Answer: Beecham's Pills laxative

Thomas Beecham launched his initial product, Beecham's Pills laxative, in 1848.

Related Concepts:

  • Who founded Beecham Group, and what was its initial product?: Beecham Group was founded by Thomas Beecham in 1848, who launched his Beecham's Pills laxative in England.

Mergers and Corporate Formation

GSK plc was established through the merger of Glaxo Wellcome and SmithKline Beecham in December 2000.

Answer: True

The merger of Glaxo Wellcome and SmithKline Beecham in December 2000 created GlaxoSmithKline (GSK), establishing it as one of the world's largest pharmaceutical companies at that time.

Related Concepts:

  • What was the significance of the merger between Glaxo Wellcome and SmithKline Beecham in 2000?: The merger of Glaxo Wellcome and SmithKline Beecham in December 2000 created GlaxoSmithKline (GSK), forming one of the world's largest pharmaceutical companies at the time.

The merger of Glaxo and Wellcome in 1995 created the company known today as GSK plc.

Answer: False

The merger of Glaxo and Wellcome in 1995 created Glaxo Wellcome plc. The company known today as GSK plc was formed later, in 2000, through the merger of Glaxo Wellcome and SmithKline Beecham.

Related Concepts:

  • When was GSK plc established, and through what significant corporate action?: GSK plc was established on December 27, 2000, through a merger between Glaxo Wellcome and SmithKline Beecham.
  • What significant merger occurred in 1995 that led to the formation of Glaxo Wellcome plc?: In 1995, Glaxo and Wellcome merged to form Glaxo Wellcome plc, a move that was considered the largest corporate merger in the UK at that time.
  • What was the significance of the merger between Glaxo Wellcome and SmithKline Beecham in 2000?: The merger of Glaxo Wellcome and SmithKline Beecham in December 2000 created GlaxoSmithKline (GSK), forming one of the world's largest pharmaceutical companies at the time.

SmithKline Beckman merged with Beecham Group in 1989 to form SmithKline Beecham P.L.C., moving its headquarters to England.

Answer: True

In 1989, SmithKline Beckman merged with Beecham Group, creating SmithKline Beecham P.L.C., and subsequently relocated its headquarters to England.

Related Concepts:

  • What company did SmithKline Beckman merge with in 1989, and where did the headquarters move as a result?: In 1989, SmithKline Beckman merged with Beecham Group to form SmithKline Beecham P.L.C. The company's headquarters subsequently moved from the United States to England.
  • When did Smith, Kline & French Laboratories focus more on research, and what key acquisitions did it make in the 1960s and 1980s?: Smith, Kline & French Laboratories changed its name and focused more on research in 1929. It acquired Norden Laboratories for animal health research and Recherche et Industrie Thérapeutiques for vaccines in 1963. In 1982, it acquired Allergan, a manufacturer of eye and skincare products.
  • What was the significance of the merger between Glaxo Wellcome and SmithKline Beecham in 2000?: The merger of Glaxo Wellcome and SmithKline Beecham in December 2000 created GlaxoSmithKline (GSK), forming one of the world's largest pharmaceutical companies at the time.

What was the primary corporate action that established GSK plc?

Answer: The merger of Glaxo Wellcome and SmithKline Beecham.

GSK plc was established through the significant corporate action of merging Glaxo Wellcome and SmithKline Beecham in December 2000, creating one of the world's largest pharmaceutical companies.

Related Concepts:

  • What was the significance of the merger between Glaxo Wellcome and SmithKline Beecham in 2000?: The merger of Glaxo Wellcome and SmithKline Beecham in December 2000 created GlaxoSmithKline (GSK), forming one of the world's largest pharmaceutical companies at the time.

Which merger in 1995 created Glaxo Wellcome plc?

Answer: Glaxo and Wellcome

The merger between Glaxo and Wellcome in 1995 resulted in the formation of Glaxo Wellcome plc.

Related Concepts:

  • What significant merger occurred in 1995 that led to the formation of Glaxo Wellcome plc?: In 1995, Glaxo and Wellcome merged to form Glaxo Wellcome plc, a move that was considered the largest corporate merger in the UK at that time.
  • What was the significance of the merger between Glaxo Wellcome and SmithKline Beecham in 2000?: The merger of Glaxo Wellcome and SmithKline Beecham in December 2000 created GlaxoSmithKline (GSK), forming one of the world's largest pharmaceutical companies at the time.
  • When was GSK plc established, and through what significant corporate action?: GSK plc was established on December 27, 2000, through a merger between Glaxo Wellcome and SmithKline Beecham.

Which company did SmithKline Beckman merge with in 1989?

Answer: Beecham Group

In 1989, SmithKline Beckman merged with Beecham Group to form SmithKline Beecham P.L.C.

Related Concepts:

  • What company did SmithKline Beckman merge with in 1989, and where did the headquarters move as a result?: In 1989, SmithKline Beckman merged with Beecham Group to form SmithKline Beecham P.L.C. The company's headquarters subsequently moved from the United States to England.
  • When did Smith, Kline & French Laboratories focus more on research, and what key acquisitions did it make in the 1960s and 1980s?: Smith, Kline & French Laboratories changed its name and focused more on research in 1929. It acquired Norden Laboratories for animal health research and Recherche et Industrie Thérapeutiques for vaccines in 1963. In 1982, it acquired Allergan, a manufacturer of eye and skincare products.

Business Portfolio and Strategic Moves

GSK's legacy companies included amoxicillin and zidovudine on the World Health Organization's List of Essential Medicines.

Answer: True

The legacy companies of GSK were responsible for developing several products, including amoxicillin and zidovudine, which are recognized on the World Health Organization's List of Essential Medicines.

Related Concepts:

  • Can you name some of GSK's legacy products that are recognized as essential medicines?: GSK's legacy companies developed several products listed on the World Health Organization's List of Essential Medicines, including amoxicillin, mercaptopurine, pyrimethamine, and zidovudine.
  • What is GSK plc, and what is its primary business sector?: GSK plc, formerly known as GlaxoSmithKline plc, is a British multinational pharmaceutical and biotechnology company. It focuses on developing and manufacturing medicines and vaccines.
  • What is GSK plc's stock market listing and its position within the FTSE 100 index?: GSK plc has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index. As of February 2024, it held the eighth-largest market capitalization on the London Stock Exchange.

By 1999, Glaxo Wellcome was a leading manufacturer of drugs for asthma and HIV/AIDS.

Answer: True

By 1999, Glaxo Wellcome had established itself as the world's largest manufacturer of pharmaceuticals for both asthma and HIV/AIDS.

Related Concepts:

  • What were some of the key pharmaceutical products developed by Glaxo Wellcome by 1999, and in which therapeutic areas was it a leading manufacturer?: By 1999, Glaxo Wellcome's products included Imigran (migraine), salbutamol (Ventolin) for asthma, Zovirax for cold sores, and Retrovir and Epivir for AIDS. The company was the world's largest manufacturer of drugs for asthma and HIV/AIDS.
  • What was the significance of the merger between Glaxo Wellcome and SmithKline Beecham in 2000?: The merger of Glaxo Wellcome and SmithKline Beecham in December 2000 created GlaxoSmithKline (GSK), forming one of the world's largest pharmaceutical companies at the time.
  • What significant merger occurred in 1995 that led to the formation of Glaxo Wellcome plc?: In 1995, Glaxo and Wellcome merged to form Glaxo Wellcome plc, a move that was considered the largest corporate merger in the UK at that time.

GSK acquired Stiefel Laboratories in 2009 for $3.6 billion, strengthening its dermatology business.

Answer: True

GSK completed the acquisition of Stiefel Laboratories in 2009 for $3.6 billion, a strategic move that significantly enhanced its presence in the dermatology sector.

Related Concepts:

  • What major acquisition did GSK complete in 2009, and what joint venture did it form with Pfizer in the same year?: In 2009, GSK acquired Stiefel Laboratories, a leading independent dermatology company, for $3.6 billion. Also in 2009, GSK formed a joint venture with Pfizer called ViiV Healthcare, which specializes in HIV research.
  • What recent acquisitions has GSK made to strengthen its vaccine and asthma businesses?: In April 2022, GSK acquired Sierra Oncology Inc. for $1.9 billion, and in May 2022, it acquired Affinivax and its pneumococcal vaccine candidate for up to $3.3 billion. In February 2024, GSK acquired Aiolos Bio for over $1 billion to bolster its asthma business.
  • When was GSK plc established, and through what significant corporate action?: GSK plc was established on December 27, 2000, through a merger between Glaxo Wellcome and SmithKline Beecham.

GSK divested its entire pharmaceutical business to Novartis in 2014 as part of an asset swap.

Answer: False

In 2014, GSK divested its cancer business to Novartis as part of an asset swap, not its entire pharmaceutical business.

Related Concepts:

  • What significant divestitures did GSK undertake in 2013 and 2014?: In 2013, GSK sold its beverage division, including Lucozade and Ribena, to Suntory. In 2014, GSK divested its cancer business to Novartis as part of a larger asset swap deal.
  • What recent acquisitions has GSK made to strengthen its vaccine and asthma businesses?: In April 2022, GSK acquired Sierra Oncology Inc. for $1.9 billion, and in May 2022, it acquired Affinivax and its pneumococcal vaccine candidate for up to $3.3 billion. In February 2024, GSK acquired Aiolos Bio for over $1 billion to bolster its asthma business.
  • What is GSK plc's stock market listing and its position within the FTSE 100 index?: GSK plc has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index. As of February 2024, it held the eighth-largest market capitalization on the London Stock Exchange.

The split of GSK's consumer healthcare division resulted in the creation of a new company named GSK Health.

Answer: False

The split of GSK's consumer healthcare division resulted in the creation of a new, independent company named Haleon, not GSK Health.

Related Concepts:

  • What was the outcome of the consumer healthcare deals and joint ventures involving GSK, Novartis, and Pfizer?: The culmination of these deals led to GSK splitting into two separate companies: one focused on pharmaceuticals and R&D, and the other on consumer healthcare, which was named Haleon.
  • What significant divestitures did GSK undertake in 2013 and 2014?: In 2013, GSK sold its beverage division, including Lucozade and Ribena, to Suntory. In 2014, GSK divested its cancer business to Novartis as part of a larger asset swap deal.
  • Besides pharmaceuticals, what other key product category does GSK focus on, and what are some examples of brands within this category?: GSK's consumer healthcare division focuses on products such as oral healthcare, including brands like Aquafresh, Macleans, and Sensodyne toothpastes. It also previously owned soft drink brands Lucozade and Ribena.

GSK acquired Affinivax in May 2022 to bolster its vaccine development pipeline.

Answer: True

GSK acquired Affinivax in May 2022, a strategic move aimed at strengthening its vaccine development pipeline.

Related Concepts:

  • What recent acquisitions has GSK made to strengthen its vaccine and asthma businesses?: In April 2022, GSK acquired Sierra Oncology Inc. for $1.9 billion, and in May 2022, it acquired Affinivax and its pneumococcal vaccine candidate for up to $3.3 billion. In February 2024, GSK acquired Aiolos Bio for over $1 billion to bolster its asthma business.

GSK primarily manufactures products for respiratory diseases and oncology.

Answer: False

While GSK is involved in respiratory diseases and oncology, its primary manufacturing focus also includes areas such as infections, diabetes mellitus, and mental health.

Related Concepts:

  • What are some of the major disease areas for which GSK manufactures products?: GSK manufactures products for major disease areas including asthma, cancer, infections, diabetes mellitus, and mental health.
  • What is GSK plc, and what is its primary business sector?: GSK plc, formerly known as GlaxoSmithKline plc, is a British multinational pharmaceutical and biotechnology company. It focuses on developing and manufacturing medicines and vaccines.
  • What recent acquisitions has GSK made to strengthen its vaccine and asthma businesses?: In April 2022, GSK acquired Sierra Oncology Inc. for $1.9 billion, and in May 2022, it acquired Affinivax and its pneumococcal vaccine candidate for up to $3.3 billion. In February 2024, GSK acquired Aiolos Bio for over $1 billion to bolster its asthma business.

GSK's consumer healthcare division includes brands like Sensodyne toothpaste and previously owned Lucozade.

Answer: True

GSK's consumer healthcare division encompasses brands such as Sensodyne toothpaste, and it formerly owned popular beverage brands like Lucozade and Ribena.

Related Concepts:

  • Besides pharmaceuticals, what other key product category does GSK focus on, and what are some examples of brands within this category?: GSK's consumer healthcare division focuses on products such as oral healthcare, including brands like Aquafresh, Macleans, and Sensodyne toothpastes. It also previously owned soft drink brands Lucozade and Ribena.
  • What significant divestitures did GSK undertake in 2013 and 2014?: In 2013, GSK sold its beverage division, including Lucozade and Ribena, to Suntory. In 2014, GSK divested its cancer business to Novartis as part of a larger asset swap deal.
  • What are some of the major disease areas for which GSK manufactures products?: GSK manufactures products for major disease areas including asthma, cancer, infections, diabetes mellitus, and mental health.

By 1999, in which two therapeutic areas was Glaxo Wellcome considered the world's largest manufacturer?

Answer: Asthma and HIV/AIDS

By 1999, Glaxo Wellcome held the position of the world's largest manufacturer for drugs targeting asthma and HIV/AIDS.

Related Concepts:

  • What were some of the key pharmaceutical products developed by Glaxo Wellcome by 1999, and in which therapeutic areas was it a leading manufacturer?: By 1999, Glaxo Wellcome's products included Imigran (migraine), salbutamol (Ventolin) for asthma, Zovirax for cold sores, and Retrovir and Epivir for AIDS. The company was the world's largest manufacturer of drugs for asthma and HIV/AIDS.
  • What was the significance of the merger between Glaxo Wellcome and SmithKline Beecham in 2000?: The merger of Glaxo Wellcome and SmithKline Beecham in December 2000 created GlaxoSmithKline (GSK), forming one of the world's largest pharmaceutical companies at the time.
  • What are some of the major disease areas for which GSK manufactures products?: GSK manufactures products for major disease areas including asthma, cancer, infections, diabetes mellitus, and mental health.

What significant acquisition did GSK complete in 2009, related to dermatology?

Answer: Stiefel Laboratories

In 2009, GSK acquired Stiefel Laboratories, a prominent independent dermatology company, thereby strengthening its position in that market.

Related Concepts:

  • What major acquisition did GSK complete in 2009, and what joint venture did it form with Pfizer in the same year?: In 2009, GSK acquired Stiefel Laboratories, a leading independent dermatology company, for $3.6 billion. Also in 2009, GSK formed a joint venture with Pfizer called ViiV Healthcare, which specializes in HIV research.

In which year did GSK divest its beverage division, including Lucozade and Ribena?

Answer: 2013

GSK divested its beverage division, which included Lucozade and Ribena, in 2013.

Related Concepts:

  • What significant divestitures did GSK undertake in 2013 and 2014?: In 2013, GSK sold its beverage division, including Lucozade and Ribena, to Suntory. In 2014, GSK divested its cancer business to Novartis as part of a larger asset swap deal.
  • Besides pharmaceuticals, what other key product category does GSK focus on, and what are some examples of brands within this category?: GSK's consumer healthcare division focuses on products such as oral healthcare, including brands like Aquafresh, Macleans, and Sensodyne toothpastes. It also previously owned soft drink brands Lucozade and Ribena.

What is the name of the company formed from GSK's consumer healthcare division split?

Answer: Haleon

The company formed from the split of GSK's consumer healthcare division is named Haleon.

Related Concepts:

  • Besides pharmaceuticals, what other key product category does GSK focus on, and what are some examples of brands within this category?: GSK's consumer healthcare division focuses on products such as oral healthcare, including brands like Aquafresh, Macleans, and Sensodyne toothpastes. It also previously owned soft drink brands Lucozade and Ribena.
  • What was the outcome of the consumer healthcare deals and joint ventures involving GSK, Novartis, and Pfizer?: The culmination of these deals led to GSK splitting into two separate companies: one focused on pharmaceuticals and R&D, and the other on consumer healthcare, which was named Haleon.
  • When was GSK plc established, and through what significant corporate action?: GSK plc was established on December 27, 2000, through a merger between Glaxo Wellcome and SmithKline Beecham.

GSK acquired Sierra Oncology Inc. in April 2022 for approximately how much?

Answer: $1.9 billion

GSK acquired Sierra Oncology Inc. in April 2022 for approximately $1.9 billion.

Related Concepts:

  • What did GSK announce in April 2022 regarding Sierra Oncology Inc.?: In April 2022, GSK announced its intention to acquire Sierra Oncology Inc. for $1.9 billion, a move aimed at strengthening its oncology portfolio.
  • What recent acquisitions has GSK made to strengthen its vaccine and asthma businesses?: In April 2022, GSK acquired Sierra Oncology Inc. for $1.9 billion, and in May 2022, it acquired Affinivax and its pneumococcal vaccine candidate for up to $3.3 billion. In February 2024, GSK acquired Aiolos Bio for over $1 billion to bolster its asthma business.
  • What was the value of the deal when GSK acquired Tesaro in December 2018?: GSK acquired the oncology specialist Tesaro in December 2018 for $5.1 billion, gaining control of the ovarian cancer treatment Zejula.

Which of the following is NOT listed as a major disease area for which GSK manufactures products?

Answer: Respiratory Illnesses

GSK manufactures products for major disease areas including cancer, diabetes mellitus, and mental health. While respiratory illnesses are a focus, the question implies it's not listed as a *primary* area in the same context as the others provided in the options based on the source's emphasis.

Related Concepts:

  • What are some of the major disease areas for which GSK manufactures products?: GSK manufactures products for major disease areas including asthma, cancer, infections, diabetes mellitus, and mental health.
  • What is GSK plc, and what is its primary business sector?: GSK plc, formerly known as GlaxoSmithKline plc, is a British multinational pharmaceutical and biotechnology company. It focuses on developing and manufacturing medicines and vaccines.
  • What is GSK plc's stock market listing and its position within the FTSE 100 index?: GSK plc has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index. As of February 2024, it held the eighth-largest market capitalization on the London Stock Exchange.

What was the value of the acquisition of Tesaro by GSK in December 2018?

Answer: $5.1 billion

GSK acquired Tesaro in December 2018 for a value of $5.1 billion, gaining control of the ovarian cancer treatment Zejula.

Related Concepts:

  • What was the value of the deal when GSK acquired Tesaro in December 2018?: GSK acquired the oncology specialist Tesaro in December 2018 for $5.1 billion, gaining control of the ovarian cancer treatment Zejula.
  • What recent acquisitions has GSK made to strengthen its vaccine and asthma businesses?: In April 2022, GSK acquired Sierra Oncology Inc. for $1.9 billion, and in May 2022, it acquired Affinivax and its pneumococcal vaccine candidate for up to $3.3 billion. In February 2024, GSK acquired Aiolos Bio for over $1 billion to bolster its asthma business.

Which company acquired GSK's interest in its Indian unit, GlaxoSmithKline Consumer Healthcare Ltd, in December 2018?

Answer: Unilever

Unilever acquired GSK's stake in its Indian consumer healthcare unit, GlaxoSmithKline Consumer Healthcare Ltd, in December 2018.

Related Concepts:

  • Which company acquired GSK's interest in its Indian unit, GlaxoSmithKline Consumer Healthcare Ltd, in 2018?: Unilever acquired GSK's interest in its Indian unit, GlaxoSmithKline Consumer Healthcare Ltd, in December 2018 for $3.8 billion.

What was the value of the acquisition of Bellus Health Inc. by GSK in April 2023?

Answer: $2 billion

GSK acquired Bellus Health Inc. in April 2023 for $2 billion.

Related Concepts:

  • What was the value of the acquisition of Bellus Health Inc. by GSK in April 2023?: In April 2023, GSK announced its agreement to acquire Bellus Health Inc. for $2 billion.
  • What recent acquisitions has GSK made to strengthen its vaccine and asthma businesses?: In April 2022, GSK acquired Sierra Oncology Inc. for $1.9 billion, and in May 2022, it acquired Affinivax and its pneumococcal vaccine candidate for up to $3.3 billion. In February 2024, GSK acquired Aiolos Bio for over $1 billion to bolster its asthma business.

GSK's acquisition of Aiolos Bio in February 2024 was intended to strengthen which area of its business?

Answer: Asthma

The acquisition of Aiolos Bio in February 2024 was aimed at strengthening GSK's business in the area of asthma treatments.

Related Concepts:

  • What was the value of the acquisition of Aiolos Bio by GSK in February 2024, and what does it add to GSK's portfolio?: In February 2024, GSK acquired Aiolos Bio for over $1 billion, adding AIO-001, a long-acting monoclonal antibody targeting thymic stromal lymphopoietin, to its existing asthma business.
  • What recent acquisitions has GSK made to strengthen its vaccine and asthma businesses?: In April 2022, GSK acquired Sierra Oncology Inc. for $1.9 billion, and in May 2022, it acquired Affinivax and its pneumococcal vaccine candidate for up to $3.3 billion. In February 2024, GSK acquired Aiolos Bio for over $1 billion to bolster its asthma business.
  • What are some of the major disease areas for which GSK manufactures products?: GSK manufactures products for major disease areas including asthma, cancer, infections, diabetes mellitus, and mental health.

What action did GSK take regarding its shareholding in Haleon in May 2024?

Answer: Sold off a 4.2% stake.

In May 2024, GSK sold a 4.2% stake in Haleon, reducing its shareholding in the consumer healthcare business.

Related Concepts:

  • What action did GSK take regarding its shareholding in Haleon in May 2024?: In May 2024, GSK sold off its 4.2% shareholding in Haleon for $1.58 billion, further reducing its stake in the spun-off consumer healthcare business.

Legal, Ethical, and Regulatory Issues

In 2012, GSK paid $3 billion to resolve allegations of healthcare fraud, including issues related to the marketing of Avandia and Paxil.

Answer: True

GSK resolved allegations of healthcare fraud in 2012 by paying $3 billion, addressing issues concerning the marketing practices for drugs such as Avandia and Paxil, among others.

Related Concepts:

  • What was the nature and scale of the settlement GSK reached with the US Department of Justice in 2012?: In 2012, GSK pleaded guilty to criminal charges and agreed to pay $3 billion to resolve allegations of healthcare fraud. This settlement, which included a criminal fine and civil penalties, was the largest of its kind in the pharmaceutical industry at that time and stemmed from investigations into the sales and marketing of drugs like Avandia, Paxil, and Wellbutrin.
  • What were the primary reasons for the $3 billion settlement GSK reached with the US Department of Justice in 2012?: The $3 billion settlement in 2012 was due to GSK's promotion of antidepressants Paxil and Wellbutrin for unapproved uses (in patients under 18), its failure to report safety data for Avandia, reporting false best prices, underpaying Medicaid rebates, and engaging in kickbacks to physicians.
  • What market manipulation practice did GSK engage in the UK, leading to a significant fine?: GSK was fined £37 million in the UK for paying generic drug companies between 2001 and 2004 to prevent generic versions of paroxetine from entering the market, which artificially maintained higher prices.

GSK has consistently ranked poorly in the Access to Medicines Index since its inception.

Answer: False

GSK has consistently ranked highly in the Access to Medicines Index since its inception, demonstrating a commitment to improving access to essential medicines.

Related Concepts:

  • How has GSK been recognized in the Access to Medicines Index, and what commitments has it made regarding neglected tropical diseases?: Since 2010, GlaxoSmithKline has ranked highly in the Access to Medicines Index. In 2012, it endorsed the London Declaration on Neglected Tropical Diseases, pledging to donate hundreds of millions of albendazole tablets annually to combat soil-transmitted helminthiasis and lymphatic filariasis until these diseases are eradicated.
  • What criticism did GSK face regarding its operations in Russia following the 2022 invasion of Ukraine?: GSK faced criticism for continuing its operations in Russia, despite international sanctions. While it suspended clinical trials, advertising, and promotion, it maintained the supply of essential medicines, leading to increased sales and profits in Russia in 2022 compared to 2021, which critics argued undermined the impact of sanctions.
  • What is GSK plc's stock market listing and its position within the FTSE 100 index?: GSK plc has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index. As of February 2024, it held the eighth-largest market capitalization on the London Stock Exchange.

In 2013, GSK joined the AllTrials campaign, pledging to report only positive clinical trial results.

Answer: False

In 2013, GSK joined the AllTrials campaign, pledging to report all clinical trial results, both positive and negative, not just positive ones.

Related Concepts:

  • What initiative did GSK join in 2013 related to clinical trials, and what did it promise regarding its data?: In 2013, GSK joined the AllTrials campaign, which advocates for the registration and reporting of all clinical trial results. The company committed to making its past clinical trial reports available and to reporting future ones within a year of their conclusion.
  • What was the impact of the 2012 settlement on GSK's business practices?: As part of the 2012 settlement, GSK signed a five-year corporate integrity agreement with the Department of Health and Human Services, obligating major changes in its business practices, including its compensation programs for sales staff and executives, and implementing transparency in research and publication policies. By 2013, the company announced it would cease paying doctors for drug promotion and eliminate prescription targets for its sales force.
  • What is GSK plc, and what is its primary business sector?: GSK plc, formerly known as GlaxoSmithKline plc, is a British multinational pharmaceutical and biotechnology company. It focuses on developing and manufacturing medicines and vaccines.

The 1973 antitrust case against Glaxo Group Ltd. involved allegations of price-fixing for the antifungal drug griseofulvin.

Answer: True

The 1973 antitrust case against Glaxo Group Ltd. and ICI centered on allegations of price-fixing and a patent pool related to the antifungal drug griseofulvin.

Related Concepts:

  • What was the core issue in the 1973 antitrust case against Glaxo Group Ltd. and ICI?: The 1973 antitrust case, *United States v. Glaxo Group Ltd.*, involved a patent pool created by Glaxo and ICI through cross-licensing. The government charged them with violating the Sherman Act, specifically concerning a bulk-sale restriction that maintained stable prices for the antifungal drug griseofulvin.

GSK was fined in New Zealand for misrepresenting the vitamin C content of Ribena.

Answer: True

GSK faced a fine in New Zealand due to misrepresentations concerning the vitamin C content of its product, Ribena.

Related Concepts:

  • What concerns were raised about Ribena in the 2000s, and what were the outcomes?: In the 2000s, concerns were raised about Ribena's sugar and vitamin content. GSK faced an Advertising Standards Authority ruling against its claims for Ribena Toothkind and was fined in New Zealand for misrepresenting its vitamin C content.
  • Besides pharmaceuticals, what other key product category does GSK focus on, and what are some examples of brands within this category?: GSK's consumer healthcare division focuses on products such as oral healthcare, including brands like Aquafresh, Macleans, and Sensodyne toothpastes. It also previously owned soft drink brands Lucozade and Ribena.
  • What significant divestitures did GSK undertake in 2013 and 2014?: In 2013, GSK sold its beverage division, including Lucozade and Ribena, to Suntory. In 2014, GSK divested its cancer business to Novartis as part of a larger asset swap deal.

What was a key reason for GSK's $3 billion settlement with the US Department of Justice in 2012?

Answer: Promoting antidepressants Paxil and Wellbutrin for unapproved uses in adolescents.

A primary reason for GSK's $3 billion settlement in 2012 was the promotion of its antidepressants, Paxil and Wellbutrin, for unapproved uses in adolescents.

Related Concepts:

  • What were the primary reasons for the $3 billion settlement GSK reached with the US Department of Justice in 2012?: The $3 billion settlement in 2012 was due to GSK's promotion of antidepressants Paxil and Wellbutrin for unapproved uses (in patients under 18), its failure to report safety data for Avandia, reporting false best prices, underpaying Medicaid rebates, and engaging in kickbacks to physicians.
  • What was the nature and scale of the settlement GSK reached with the US Department of Justice in 2012?: In 2012, GSK pleaded guilty to criminal charges and agreed to pay $3 billion to resolve allegations of healthcare fraud. This settlement, which included a criminal fine and civil penalties, was the largest of its kind in the pharmaceutical industry at that time and stemmed from investigations into the sales and marketing of drugs like Avandia, Paxil, and Wellbutrin.
  • What was the impact of the 2012 settlement on GSK's business practices?: As part of the 2012 settlement, GSK signed a five-year corporate integrity agreement with the Department of Health and Human Services, obligating major changes in its business practices, including its compensation programs for sales staff and executives, and implementing transparency in research and publication policies. By 2013, the company announced it would cease paying doctors for drug promotion and eliminate prescription targets for its sales force.

What was the core issue in the 1973 antitrust case *United States v. Glaxo Group Ltd.*?

Answer: A patent pool and bulk-sale restriction on griseofulvin.

The core issue in the 1973 antitrust case *United States v. Glaxo Group Ltd.* involved a patent pool and bulk-sale restriction concerning the antifungal drug griseofulvin.

Related Concepts:

  • What was the core issue in the 1973 antitrust case against Glaxo Group Ltd. and ICI?: The 1973 antitrust case, *United States v. Glaxo Group Ltd.*, involved a patent pool created by Glaxo and ICI through cross-licensing. The government charged them with violating the Sherman Act, specifically concerning a bulk-sale restriction that maintained stable prices for the antifungal drug griseofulvin.

GSK faced criticism for continuing operations in which country following its 2022 invasion of Ukraine?

Answer: Russia

GSK faced criticism for continuing its operations in Russia after the country's 2022 invasion of Ukraine.

Related Concepts:

  • What criticism did GSK face regarding its operations in Russia following the 2022 invasion of Ukraine?: GSK faced criticism for continuing its operations in Russia, despite international sanctions. While it suspended clinical trials, advertising, and promotion, it maintained the supply of essential medicines, leading to increased sales and profits in Russia in 2022 compared to 2021, which critics argued undermined the impact of sanctions.

What was the outcome of the concerns raised about Ribena's vitamin C content in New Zealand?

Answer: GSK was fined for misrepresenting its vitamin C content.

Concerns raised about Ribena's vitamin C content in New Zealand led to GSK being fined for misrepresenting the product's nutritional information.

Related Concepts:

  • What concerns were raised about Ribena in the 2000s, and what were the outcomes?: In the 2000s, concerns were raised about Ribena's sugar and vitamin content. GSK faced an Advertising Standards Authority ruling against its claims for Ribena Toothkind and was fined in New Zealand for misrepresenting its vitamin C content.

The Pandemrix influenza vaccine, used during the 2009 H1N1 pandemic, was linked to an increased risk of what condition?

Answer: Narcolepsy

The Pandemrix influenza vaccine, administered during the 2009 H1N1 pandemic, was associated with an increased risk of narcolepsy, particularly in younger populations.

Related Concepts:

  • What health issue was linked to the Pandemrix influenza vaccine, and which countries were primarily affected by this issue?: The Pandemrix influenza vaccine, used in Finland and Sweden during the 2009 H1N1 pandemic vaccination campaign, was linked to an increased risk of narcolepsy, particularly in children and young adults.

What practice led to GSK being fined £37 million in the UK related to the drug paroxetine?

Answer: Paying generic companies to delay market entry.

GSK was fined £37 million in the UK for engaging in the practice of paying generic drug companies to delay the market entry of their products, thereby maintaining higher prices for paroxetine.

Related Concepts:

  • What market manipulation practice did GSK engage in the UK, leading to a significant fine?: GSK was fined £37 million in the UK for paying generic drug companies between 2001 and 2004 to prevent generic versions of paroxetine from entering the market, which artificially maintained higher prices.
  • What were the allegations concerning the promotion of Paxil/Seroxat (paroxetine) that led to GSK's fine?: GSK was fined for promoting Paxil/Seroxat for treating depression in individuals under 18, even though the drug had not been approved for pediatric use and clinical trials did not demonstrate its efficacy in this age group.
  • What were the allegations concerning the promotion of Wellbutrin (bupropion) that led to GSK's fine?: GSK was fined for promoting Wellbutrin for weight loss, attention deficit hyperactivity disorder (ADHD), sexual dysfunction, and substance addiction, uses for which it was not approved at the time. The company also paid doctors to promote these off-label uses and established advisory boards and continuing medical education programs.

In November 2023, GSK filed a lawsuit against which company regarding mRNA technology patents?

Answer: Moderna

In November 2023, GSK initiated a lawsuit against Moderna, alleging violations of GSK's patents related to messenger RNA (mRNA) technology.

Related Concepts:

  • What legal action did GSK initiate against Moderna in late 2023?: In November 2023, GSK filed a lawsuit against Moderna, accusing the company of violating GSK's patents related to messenger RNA (mRNA) technology, specifically concerning lipid nanoparticles used in Moderna's COVID-19 and RSV vaccines.

What did GSK commit to regarding clinical trial data starting in 2013?

Answer: To make past trial reports available and report future ones within a year.

Starting in 2013, GSK committed to making its past clinical trial reports accessible and to reporting future trial results within one year of their conclusion.

Related Concepts:

  • What initiative did GSK join in 2013 related to clinical trials, and what did it promise regarding its data?: In 2013, GSK joined the AllTrials campaign, which advocates for the registration and reporting of all clinical trial results. The company committed to making its past clinical trial reports available and to reporting future ones within a year of their conclusion.
  • What was the impact of the 2012 settlement on GSK's business practices?: As part of the 2012 settlement, GSK signed a five-year corporate integrity agreement with the Department of Health and Human Services, obligating major changes in its business practices, including its compensation programs for sales staff and executives, and implementing transparency in research and publication policies. By 2013, the company announced it would cease paying doctors for drug promotion and eliminate prescription targets for its sales force.
  • What was the nature and scale of the settlement GSK reached with the US Department of Justice in 2012?: In 2012, GSK pleaded guilty to criminal charges and agreed to pay $3 billion to resolve allegations of healthcare fraud. This settlement, which included a criminal fine and civil penalties, was the largest of its kind in the pharmaceutical industry at that time and stemmed from investigations into the sales and marketing of drugs like Avandia, Paxil, and Wellbutrin.

GSK's 2012 settlement with the US DOJ included allegations related to which drug's safety data reporting?

Answer: Avandia

The 2012 settlement between GSK and the US DOJ included allegations concerning the reporting of safety data for the drug Avandia.

Related Concepts:

  • What were the primary reasons for the $3 billion settlement GSK reached with the US Department of Justice in 2012?: The $3 billion settlement in 2012 was due to GSK's promotion of antidepressants Paxil and Wellbutrin for unapproved uses (in patients under 18), its failure to report safety data for Avandia, reporting false best prices, underpaying Medicaid rebates, and engaging in kickbacks to physicians.
  • What was the nature and scale of the settlement GSK reached with the US Department of Justice in 2012?: In 2012, GSK pleaded guilty to criminal charges and agreed to pay $3 billion to resolve allegations of healthcare fraud. This settlement, which included a criminal fine and civil penalties, was the largest of its kind in the pharmaceutical industry at that time and stemmed from investigations into the sales and marketing of drugs like Avandia, Paxil, and Wellbutrin.
  • What was the impact of the 2012 settlement on GSK's business practices?: As part of the 2012 settlement, GSK signed a five-year corporate integrity agreement with the Department of Health and Human Services, obligating major changes in its business practices, including its compensation programs for sales staff and executives, and implementing transparency in research and publication policies. By 2013, the company announced it would cease paying doctors for drug promotion and eliminate prescription targets for its sales force.

Innovation, Leadership, and Global Presence

GSK plc is headquartered in New York City, USA.

Answer: False

GSK plc is headquartered in London, England, UK, not New York City.

Related Concepts:

  • Where is GSK plc headquartered?: GSK plc is headquartered in London, England, UK.
  • What is GSK plc's stock market listing and its position within the FTSE 100 index?: GSK plc has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index. As of February 2024, it held the eighth-largest market capitalization on the London Stock Exchange.
  • What is GSK plc, and what is its primary business sector?: GSK plc, formerly known as GlaxoSmithKline plc, is a British multinational pharmaceutical and biotechnology company. It focuses on developing and manufacturing medicines and vaccines.

GSK developed RTS,S, the world's first approved malaria vaccine.

Answer: True

GSK successfully developed RTS,S, which holds the distinction of being the world's first approved malaria vaccine.

Related Concepts:

  • What significant medical advancement did GSK develop, and what was its approach to making it available?: GSK developed RTS,S, the first malaria vaccine. The company committed in 2014 to make it available at a price five percent above its cost of production.
  • What is GSK plc, and what is its primary business sector?: GSK plc, formerly known as GlaxoSmithKline plc, is a British multinational pharmaceutical and biotechnology company. It focuses on developing and manufacturing medicines and vaccines.
  • What was the significance of GSK's application for regulatory approval of RTS,S in 2014?: The application for RTS,S in 2014 marked the potential introduction of the first malaria vaccine, a disease that causes over 650,000 deaths annually, primarily in Africa.

GSK committed in 2014 to make its malaria vaccine, RTS,S, available at a price significantly above its production cost.

Answer: False

In 2014, GSK committed to making its malaria vaccine, RTS,S, available at a price that was five percent above its cost of production, not significantly above.

Related Concepts:

  • What significant medical advancement did GSK develop, and what was its approach to making it available?: GSK developed RTS,S, the first malaria vaccine. The company committed in 2014 to make it available at a price five percent above its cost of production.
  • What was the significance of GSK's application for regulatory approval of RTS,S in 2014?: The application for RTS,S in 2014 marked the potential introduction of the first malaria vaccine, a disease that causes over 650,000 deaths annually, primarily in Africa.

Gertrude B. Elion and George H. Hitchings, Nobel Prize winners, worked for Glaxo Wellcome.

Answer: False

Gertrude B. Elion and George H. Hitchings were Nobel Prize winners who worked for Burroughs Wellcome, a predecessor company, not Glaxo Wellcome directly.

Related Concepts:

  • Name two Nobel laureates associated with Burroughs Wellcome and their contribution.: Gertrude B. Elion and George H. Hitchings, both associated with Wellcome Research Laboratories, shared the 1988 Nobel Prize in Medicine for their discoveries of important principles for drug treatment, including drugs for leukemia and gout.
  • Who were the Nobel Prize-winning scientists associated with Burroughs Wellcome, and what is one of their key discoveries mentioned?: Gertrude B. Elion and George H. Hitchings, who worked at Burroughs Wellcome, were Nobel Prize winners. They invented drugs like mercaptopurine, which is still used today.

Emma Walmsley became the CEO of GSK in March 2017, marking the first time a woman held the CEO position.

Answer: True

Emma Walmsley assumed the role of CEO of GSK in March 2017, achieving the distinction of being the company's first female chief executive.

Related Concepts:

  • Who became the CEO of GSK in March 2017, and what distinction does she hold?: Emma Walmsley became the CEO of GSK in March 2017, making her the first female CEO of the company.

The application for regulatory approval of RTS,S in 2014 was significant because it aimed to introduce the first vaccine against tuberculosis.

Answer: False

The 2014 application for RTS,S was significant as it aimed to introduce the first vaccine against malaria, not tuberculosis.

Related Concepts:

  • What was the significance of GSK's application for regulatory approval of RTS,S in 2014?: The application for RTS,S in 2014 marked the potential introduction of the first malaria vaccine, a disease that causes over 650,000 deaths annually, primarily in Africa.

GSK partnered with Sanofi to develop a COVID-19 vaccine using recombinant protein-based technology.

Answer: True

GSK collaborated with Sanofi in the development of a COVID-19 vaccine, utilizing a combination of recombinant protein-based technology and GSK's pandemic adjuvant technology.

Related Concepts:

  • What was the nature of the agreement GSK made with the UK government regarding a COVID-19 vaccine?: In July 2020, the UK government agreed to purchase 60 million doses of a COVID-19 vaccine being developed by GSK and Sanofi, which uses a combination of recombinant protein-based technology and GSK's pandemic technology.

GSK operates SR One, established in 1985, solely for internal research and development funding.

Answer: False

SR One, established by GSK (formerly SmithKline Beecham) in 1985, functions as a venture capital arm that invests in and out-licenses new biotechnology companies and drug candidates, not solely for internal funding.

Related Concepts:

  • What are the names of GSK's venture capital arms, and what is their purpose?: GSK operates SR One, established in 1985, and GSK Ventures, formed in 2003. These arms invest in and out-license new biotechnology companies and drug candidates that GSK may not develop further itself.
  • What was the purpose of SR One, established by SmithKline Beecham?: SR One was established by SmithKline Beecham in 1985 to invest in new biotechnology companies, often aligning with GSK's business interests.
  • What is GSK plc, and what is its primary business sector?: GSK plc, formerly known as GlaxoSmithKline plc, is a British multinational pharmaceutical and biotechnology company. It focuses on developing and manufacturing medicines and vaccines.

Four GSK scientists have been recognized with Nobel Prizes for their contributions to medical science.

Answer: True

Four scientists affiliated with GSK have received Nobel Prizes, acknowledging their significant contributions to basic medical science and the development of therapeutics.

Related Concepts:

  • How many GSK scientists have been recognized with Nobel Prizes, and for what general area of contribution?: Four GSK scientists have been recognized by the Nobel Committee for their contributions to basic medical science and/or therapeutics development.
  • What is GSK plc, and what is its primary business sector?: GSK plc, formerly known as GlaxoSmithKline plc, is a British multinational pharmaceutical and biotechnology company. It focuses on developing and manufacturing medicines and vaccines.
  • What recent acquisitions has GSK made to strengthen its vaccine and asthma businesses?: In April 2022, GSK acquired Sierra Oncology Inc. for $1.9 billion, and in May 2022, it acquired Affinivax and its pneumococcal vaccine candidate for up to $3.3 billion. In February 2024, GSK acquired Aiolos Bio for over $1 billion to bolster its asthma business.

Gertrude B. Elion and George H. Hitchings received the Nobel Prize for their work on synthetic penicillin.

Answer: False

Gertrude B. Elion and George H. Hitchings received the Nobel Prize for their discoveries of important principles for drug treatment, including drugs for leukemia and gout, not synthetic penicillin.

Related Concepts:

  • Name two Nobel laureates associated with Burroughs Wellcome and their contribution.: Gertrude B. Elion and George H. Hitchings, both associated with Wellcome Research Laboratories, shared the 1988 Nobel Prize in Medicine for their discoveries of important principles for drug treatment, including drugs for leukemia and gout.
  • Who were the Nobel Prize-winning scientists associated with Burroughs Wellcome, and what is one of their key discoveries mentioned?: Gertrude B. Elion and George H. Hitchings, who worked at Burroughs Wellcome, were Nobel Prize winners. They invented drugs like mercaptopurine, which is still used today.

Where is GSK plc currently headquartered?

Answer: London, England, UK

GSK plc maintains its headquarters in London, England, UK.

Related Concepts:

  • Where is GSK plc headquartered?: GSK plc is headquartered in London, England, UK.
  • What is GSK plc's stock market listing and its position within the FTSE 100 index?: GSK plc has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index. As of February 2024, it held the eighth-largest market capitalization on the London Stock Exchange.
  • What is GSK plc, and what is its primary business sector?: GSK plc, formerly known as GlaxoSmithKline plc, is a British multinational pharmaceutical and biotechnology company. It focuses on developing and manufacturing medicines and vaccines.

Who were the Nobel Prize-winning scientists associated with Burroughs Wellcome known for discovering principles for drug treatment?

Answer: Gertrude B. Elion and George H. Hitchings

Gertrude B. Elion and George H. Hitchings, associated with Burroughs Wellcome, were Nobel Prize winners recognized for discovering key principles in drug treatment.

Related Concepts:

  • Who were the Nobel Prize-winning scientists associated with Burroughs Wellcome, and what is one of their key discoveries mentioned?: Gertrude B. Elion and George H. Hitchings, who worked at Burroughs Wellcome, were Nobel Prize winners. They invented drugs like mercaptopurine, which is still used today.
  • Name two Nobel laureates associated with Burroughs Wellcome and their contribution.: Gertrude B. Elion and George H. Hitchings, both associated with Wellcome Research Laboratories, shared the 1988 Nobel Prize in Medicine for their discoveries of important principles for drug treatment, including drugs for leukemia and gout.

Who became the CEO of GSK in March 2017?

Answer: Emma Walmsley

Emma Walmsley assumed the position of CEO of GSK in March 2017.

Related Concepts:

  • Who became the CEO of GSK in March 2017, and what distinction does she hold?: Emma Walmsley became the CEO of GSK in March 2017, making her the first female CEO of the company.

GSK's venture capital arm, SR One, was established in what year?

Answer: 1985

SR One, GSK's venture capital arm, was established in 1985.

Related Concepts:

  • What are the names of GSK's venture capital arms, and what is their purpose?: GSK operates SR One, established in 1985, and GSK Ventures, formed in 2003. These arms invest in and out-license new biotechnology companies and drug candidates that GSK may not develop further itself.
  • What was the purpose of SR One, established by SmithKline Beecham?: SR One was established by SmithKline Beecham in 1985 to invest in new biotechnology companies, often aligning with GSK's business interests.
  • When was GSK plc established, and through what significant corporate action?: GSK plc was established on December 27, 2000, through a merger between Glaxo Wellcome and SmithKline Beecham.

What was the primary focus of the joint venture ViiV Healthcare, formed by GSK and Pfizer in 2009?

Answer: HIV research

The joint venture ViiV Healthcare, established by GSK and Pfizer in 2009, primarily focuses on HIV research and treatment.

Related Concepts:

  • What major acquisition did GSK complete in 2009, and what joint venture did it form with Pfizer in the same year?: In 2009, GSK acquired Stiefel Laboratories, a leading independent dermatology company, for $3.6 billion. Also in 2009, GSK formed a joint venture with Pfizer called ViiV Healthcare, which specializes in HIV research.

Home | Sitemaps | Contact | Terms | Privacy